BioMarin Shares Remain at Lows Despite Piper Jaffray Note Defending News of Clovis, Tesaro Data Updates at ASCO, Says BioMarin's BMN-673 'Looks Competitive;' Reiterates Overweight, $70 Target
Paul Quintaro